Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 74-82

  Conlon, Kevin C ^a   Lugli, Enrico ^b   Welles, Hugh C ^b,d   Rosenberg, Steven A ^a   Fojo, Antonio Tito ^a   Morris, John C ^a   Fleisher, Thomas A ^a   Dubois, Sigrid P ^a   Perera, Liyanage P ^a   Stewart, Donn M ^a   Goldman, Carolyn K ^a   Bryant, Bonita R ^a   Decker, Jean M ^a   Chen, Jing ^a   Worthy, Tat'Yana A ^a   Figg, William D ^a   Peer, Cody J ^a   Sneller, Michael C ^b   Lane, H Clifford ^b   Yovandich, Jason L ^c   Creekmore, Stephen P ^c   Roederer, Mario ^b   Waldmann, Thomas A ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 15; IL15 PROTEIN, HUMAN; INTERLEUKIN 15; RECOMBINANT PROTEIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BOLUS INJECTION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR DISTRIBUTION; CHILL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE CLEARANCE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; KIDNEY CANCER; LUNG LESION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PROTEIN BLOOD LEVEL; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; VERY ELDERLY; VOLUME OF DISTRIBUTION; WEIGHT GAIN; ADULT; CELL PROLIFERATION; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METASTASIS; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPENIA; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920577302     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.3329     Document Type: Article

References (40)

1. Rosenberg SA, Yang JC, Topalian S.L., et al.: Treatment of 283 consecutive patients with meta-static melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907-913, 1994
2. Lenardo MJ: Fas and the art of lymphocyte maintenance. J Exp Med 183:721-724, 1996
3. + Treg cells fit. Nat Immunol 6:1071-1072, 2005
4. Waldmann TA, Lugli E, Roederer M., et al. Safety (toxicity), pharmacokinetics, immunogenicity and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117:4787-4795, 2011
5. Burton JD, Bamford RN, Peters C, et al.: A lymphokine, provisionally designated interleukin-T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer-cells. Proc Natl Acad Sci U S A 91:4935-4939, 1994
6. Grabstein KH, Eisenman J, Shanebeck K., et al.: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2. Science 264:965-968, 1994
7. Bamford RN, Grant AJ, Burton J.D., et al.: The interleukin IL(2) receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A 91:4940-4944, 1994
8. Waldmann TA: The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nature Reviews Immunol 6:595-601, 2006
9. Giri JG, Kumaki S, Ahdieh M., et al.: Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 14:3654-3663, 1995
10. Sugamura K, Asao H, Kondo M., et al.: The interleukin-2 receptor gamma chain: Its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14:179-205, 1996
11. Noguchi M, Nakamura Y, Russell S.M., et al.: Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor. Science 262:1877-1880, 1993
12. Waldmann TA, Tagaya Y: The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17:19-49, 1999
13. Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunity 14:105-110, 2001
14. Fehniger TA, Cooper MA, Caligiuri MA: Interleukin-2 and interleukin-15: Immunotherapy for cancer. Cytokine Growth Factor Rev 13:169-183, 2002
15. Sadlack B, Kühn R, Schorle H., et al.: Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and-4. Eur J Immunol 24:281-284, 1994
16. Kennedy MK, Glaccum M, Brown S.N., et al.: Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771-780, 2000
17. Marks-Koncalik J, Dubois S, Losi J.M., et al.: IL-2 induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 97:11445-11450, 2000
18. Dubois S, Mariner J, Waldmann T.A., et al. L-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17:537-547, 2002
19. Burkett PR, Koka R, Chien M., et al.: Coordinate expression and trans presentation of interleukin (IL)-15R alpha and IL-15 supports natural killer cell and memory CD8(+) T cell homeostasis. J Exp Med 200:825-834, 2004
20. Sandau MM, Schluns KS, Lefrancois L, et al. Cutting edge: Transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R by the same cells. J Immunol 173:6537-6541, 2004
21. Kobayashi H, Dubois S, Sato N., et al.: Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:721-727, 2005
22. Munger W, DeJoy SQ, Jeyaseelan R Sr, et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2. Cell Immunol 165:289-293, 1995
23. Evans R, Fuller JA, Christianson G, et al.: IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations. Cell Immunol 179:66-73, 1997
24. Klebanoff CA, Finkelstein SE, Surman D.R., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101 1969-1974, 2004
25. Zeng R, Spolski R, Finkelstein S.E., et al.: Synergy of IL-21 and IL-15 in regulating CD8(+) T cell expansion and function. J Exper Med 201:139-148, 2005
26. Becker TC, Wherry EJ, Boone D, et al.: Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195:1541-1548, 2002
27. Kudo-Saito C, Wansley EK, Gruys M.E., et al.: Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res 13:1936-1946, 2007
28. Zhang M, Ju W, Yao Z., et al.: Interleukin-15(IL-15) combined with an agonistic anti-CD40 antibody that augments IL-15Rα expression leads to regression of established TRAMP-C2 tumors in mice J Immunol 188:6156-6164, 2012
29. Yu P, Steel JC, Zhang M, et al.: Simultaneous nhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model Proc Natl Acad Sci U S A 109:6187-6192, 2012
30. Sneller MC, Kopp WC, Kory J, et al.: IL-15 administered by continuous intravenous infusion to rhesus macaques induces massive expansion of the CD8+ T effector memory population in peripheral blood. Blood 118:6845-6848, 2011
31. Lugli E, Goldman CK, Perera L.P., et al.: Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood 116: 3238-3248, 2010
32. Roederer M, Nozzi JL, Nason MC: SPICE Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79:167-174, 2011
33. + regulatory T cells in cancer patients. Blood 107:2409-2414, 2006
34. Wei S, Kryczek l, Edwards R.P., et al. Interleukin-2 administration alters the CD4+FoxP3 + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67:7487-7494, 2007
35. Choo Sim G, Martin-Orozco N, Jin L., et al.: IL-2 therapy promotes suppressive ICOS+ T reg expansion in melanoma patients. J Clin Invest 124:99-110, 2014
36. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169-1177, 2006
37. Teachey DT, Rheingold SR, Maude S.L., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121:5154-5157, 2013
38. Grupp SA, Kalos M, Barrett D., et al.: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013
39. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38, 2013
40. Krüttgen A, Rose-John S: Interleukin-6 in sep-sis and capillary leak syndrome. J Interferon Cytokine Res 32:60-65, 2012